Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 18INDUSTRY 5NIH 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 20Lymphoid 5Other hematologic neoplasm 3Myeloid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 9Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Methotrexate 5fludarabine 4nilotinib 3merphos 3fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Polymerase Chain Reaction 3Mitoxantrone 3Melphalan 3Idarubicin 3Daunorubicin 3Cytogenetic Analysis 3Cyclosporine 3Asparaginase 3bosutinib 2Thioguanine 2Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lenalidomide × Myeloid × Clear all
NCT01556477 2012-03-16

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Nordic MDS Group

Phase 2 Unknown
72 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡